title: Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit.
abstract: The relapse patterns of 29 patients who recurred following treatment for metastatic germ cell tumours of the testis (seminoma n = 7, non-seminomatous germ cell tumour n = 22) have been analysed and the relative effectiveness of clinical follow-up and routine investigations in detecting relapse at an early stage have been examined. The analysis shows that routine estimation of the serum tumour markers human chorionic gonadotrophin and alpha-foetoprotein (HCG and AFP) is the single most important follow-up procedure. This is so, even in patients who were previously marker negative; it was the first indicator of relapse in 55% of the patients. Regular clinical examination and chest radiograph in asymptomatic patients was of little value. Chest radiograph gave the first evidence of relapse in only 2 cases (7%). The optimum frequency for follow-up computed tomographic scanning of the chest and abdomen remains debatable. In this series, it was the first abnormal investigation in 7 patients (24%) and proved to be particularly important in patients who had residual radiological abnormalities at the end of initial therapy. Cost analysis shows that intensive follow-up produces a total expenditure on investigations of approximately 4,500 pounds per relapse detected. Regular computed tomographic scanning is especially demanding on resources and costs approximately 12,880 pounds per relapse detected if the recommended protocol is followed.
authors.affiliation: University Department of Radiotherapy and Oncology, Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, UK.
authors.forename: A J
authors.initials: AJ
authors.lastname: Rathmell
authors.forename: I R
authors.initials: IR
authors.lastname: Brand
authors.forename: B M
authors.initials: BM
authors.lastname: Carey
authors.forename: W G
authors.initials: WG
authors.lastname: Jones
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D003365:Costs and Cost Analysis; D004407:Dysgerminoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008485:Medical Audit; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009373:Neoplasms, Germ Cell and Embryonal / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D013736:Testicular Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins